Astellas Pharma Inc.

BMV:4503 N Stock Report

Market Cap: Mex$303.4b

Astellas Pharma Management

Management criteria checks 3/4

Astellas Pharma's CEO is Naoki Okamura, appointed in Apr 2023, has a tenure of 4.83 years. total yearly compensation is ¥204.00M, comprised of 34.3% salary and 65.7% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth MX$5.58M. The average tenure of the management team and the board of directors is 3.3 years and 2.5 years respectively.

Key information

Naoki Okamura

Chief executive officer

JP¥204.0m

Total compensation

CEO salary percentage34.3%
CEO tenureless than a year
CEO ownership0.002%
Management average tenure3.3yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Naoki Okamura's remuneration changed compared to Astellas Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

JP¥4b

Sep 30 2023n/an/a

JP¥38b

Jun 30 2023n/an/a

JP¥107b

Mar 31 2023JP¥204mJP¥70m

JP¥99b

Dec 31 2022n/an/a

JP¥136b

Sep 30 2022n/an/a

JP¥149b

Jun 30 2022n/an/a

JP¥118b

Mar 31 2022n/an/a

JP¥124b

Dec 31 2021n/an/a

JP¥120b

Sep 30 2021n/an/a

JP¥119b

Jun 30 2021n/an/a

JP¥101b

Mar 31 2021JP¥236mJP¥70m

JP¥121b

Dec 31 2020n/an/a

JP¥138b

Sep 30 2020n/an/a

JP¥140b

Jun 30 2020n/an/a

JP¥187b

Mar 31 2020JP¥232mJP¥53m

JP¥195b

Compensation vs Market: Naoki's total compensation ($USD1.34M) is below average for companies of similar size in the MX market ($USD5.89M).

Compensation vs Earnings: Naoki's compensation has been consistent with company performance over the past year.

CEO

Naoki Okamura (61 yo)

less than a year

Tenure

JP¥204,000,000

Compensation

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...

Leadership Team

NamePositionTenureCompensationOwnership
Naoki Okamura
Presidentless than a yearJP¥204.00m0.0018%
MX$ 5.6m
Atsushi Kitamura
Chief Financial Officer1.3yrsno datano data
Nobue Yasuda
General Manager of Finance & Accounting Departmentno datano datano data
Yoshitsugu Shitaka
Chief Scientific Officer & Senior Managing Executive Officer3.3yrsno datano data
Catherine Levitt
General Counselno datano datano data
Katsuyoshi Sugita
Chief People Officer2.9yrsno data0.000060%
MX$ 182.1k
Stig Ogata
Vice President of Corporate Communications6yrsno datano data
Collette Taylor
Senior Vice President of Human Resourcesno datano datano data
Tatjana Dragovic
Senior VP and Head of Ethics & Compliance6.1yrsno datano data
Nobuaki Tanaka
President of Japan Commercial & Senior Corporate Executive7.8yrsno datano data
Jun Kono
Head of Japan Commercialless than a yearno datano data
Andrew Krivoshik
Senior VP & Therapeutic Area and Head for Oncology5yrsno datano data

3.3yrs

Average Tenure

60yo

Average Age

Experienced Management: 4503 N's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Naoki Okamura
President4.8yrsJP¥204.00m0.0018%
MX$ 5.6m
Katsuyoshi Sugita
Chief People Officerless than a yearno data0.000060%
MX$ 182.1k
Takashi Tanaka
Independent Outside Director2.8yrsno datano data
Kenji Yasukawa
Chairman of the Board6.8yrsJP¥452.00m0.0071%
MX$ 21.5m
Raita Takahashi
Independent Outside Director3.8yrsno datano data
Eriko Sakurai
Independent Outside Director2.3yrsno datano data
Mika Nakayama
Independent Outside Director2.3yrsno datano data
Toru Yoshimitsu
Director3.8yrsno data0.0026%
MX$ 8.0m
Rie Akiyama
Outside Independent Directorless than a yearno datano data
Yoichi Ohno
Outside Independent Directorless than a yearno datano data

2.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 4503 N's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/10 05:02
End of Day Share Price 2024/01/12 00:00
Earnings2023/12/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astellas Pharma Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research